Market Context — Why This Technology, Why Now

The biomedical research landscape is rapidly evolving, driven by intense competition in drug discovery and the growing sophistication of regenerative medicine. There's a critical need for technologies that enhance research efficiency, reduce operational costs, and improve data quality for advanced analytics, including AI-driven diagnostics. This technology directly addresses these pressures by streamlining sample preparation, enabling faster experimental cycles, and providing clearer 3D biological insights, crucial for maintaining a competitive edge and accelerating breakthroughs.

Key Competitive Advantages
01

Simplifies processing and enables high-throughput analysis, significantly boosting research productivity by clearing multiple samples simultaneously without specialized equipment or complex procedures.

02

Enables high-precision low-magnification imaging, allowing clear observation of fine cellular and tissue structures across wide fields, contributing to comprehensive macroscopic understanding.

03

Provides a robust and stable IP foundation, having overcome 8 prior art references and two office actions, ensuring a strong and defensible patent for stable business operations.

Market Opportunity
Drug Discovery Research & Development
$5B–$6B globally (AI est.)
As demand for higher success rates and shorter development times in new drug development grows, efficient high-throughput screening of multiple samples is essential. This technology has the potential to accelerate candidate substance evaluation cycles and speed up market entry.
Pharmaceutical R&D departments Contract Research Organizations (CROs) Biotech startups in drug screening
Regenerative Medicine & Tissue Engineering
$1.5B–$2.5B globally (AI est.)
There is a growing demand for non-destructive, high-resolution 3D imaging in evaluating the quality of regenerated tissues and analyzing engraftment mechanisms after transplantation. This technology streamlines these evaluation processes.
Regenerative medicine companies Tissue engineering research institutes Medical device manufacturers for implants
Pathology Diagnostics & Medical Devices
$300M–$400M domestically (AI est.)
Improving the accuracy of tissue observation in pathology diagnostics directly leads to reduced misdiagnosis risk and earlier detection. The clear images provided by this technology also contribute to improving the accuracy of AI diagnostics and promote DX in medical settings.
Diagnostic imaging equipment manufacturers Pathology lab service providers AI medical software developers
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a specific composition and its utilization method for biomaterial clearing. It demonstrates strong validity, having successfully navigated two office actions and eight prior art references during examination, indicating a robust and difficult-to-invalidate intellectual property asset.

Competitive White Space

This patent focuses on the clearing composition and method. White space exists in developing specialized imaging hardware optimized for cleared tissues, AI-driven analytical software for 3D datasets, or integrated microfluidic systems for automated high-throughput sample preparation.

Economic Impact
~$200K/year estimated R&D cost reduction per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Traditional complex clearing processes required an average of 8 hours per sample, totaling 16,000 hours for 2,000 samples annually. By reducing processing time by 50% (saving 8,000 hours) with this technology, and assuming an average researcher labor cost of ~$50K/year (AI est.), an annual cost reduction of ~$200K (AI est.) is projected. This could lead to an estimated 15% reduction in annual R&D costs.

Speed to Market
6× faster than in-house development
This technology has been validated by RIKEN, with existing licensing track record. Its core performance and application scope are established, allowing licensees to significantly reduce development time compared to starting from scratch. Integration is straightforward, requiring only the incorporation of the solution into existing research workflows, enabling rapid deployment and business expansion. A technology that would take over 3 years for in-house development could reach the commercialization phase in approximately six months.
Competitive Positioning

X: Analysis Efficiency (High-Throughput)
Y: Imaging Quality (High Resolution)

Business Models & Applications
🔬 Integration into In-house R&D
Integrate this technology into existing R&D pipelines to maximize biomaterial analysis efficiency and accelerate the development of new products and technologies.
🤝 Contract Research Services
Offer high-throughput clearing and imaging analysis services to third parties, securing new revenue streams and establishing specialized market expertise.
🧪 Clearing Reagent/Kit Sales
Develop and sell clearing reagents and kits based on this technology's composition to research institutions and pharmaceutical companies, reaching a broad customer base and gaining market share.
Adjacent Application Opportunities
🏥 医療診断
High-Precision Pathology Diagnostic Support
Combining cleared biological tissues with AI image analysis could create systems that visualize subtle lesions and 3D structures, often missed in conventional thin sections. This has the potential to dramatically improve diagnostic accuracy by an estimated 20-30%.
💊 製薬・創薬
Accelerated Drug Screening Platform
Develop a platform for high-throughput 3D imaging to evaluate the effects of numerous drug candidates on biological materials. This could shorten drug development timelines by 15-20% and significantly reduce associated costs.
🧪 化粧品・食品科学
Enhanced Product Functionality & Safety Evaluation
Utilize clearing technology for detailed analysis of cosmetic ingredients or food additives on skin and digestive tissues. This could streamline product functionality and safety evaluations, potentially reducing testing cycles by 25% and boosting competitive development.
Integration Roadmap — Estimated 12-Month Deployment
Technology Evaluation & Prototype Construction
Duration: 3 months
Optimize the technology's composition for the licensee's existing biomaterials and analytical instruments, then build a prototype. Evaluate clearing efficiency and imaging quality with a small sample set.
Demonstration Experiment & Workflow Integration
Duration: 6 months
Conduct large-scale demonstration experiments with the prototype to confirm reproducibility and stability across diverse biomaterials. Integrate and standardize the technology within existing research workflows.
Full-Scale Operation & Business Expansion
Duration: 3 months
Transition the optimized technology and workflow to full-scale operation, maximizing R&D efficiency. Progress into business expansion phases, including new contract research services or reagent sales.
Technical Feasibility
This technology is a chemical process utilizing a solution with specific compounds, requiring no specialized hardware or significant capital investment. Licensees can leverage existing lab equipment. The patent clearly defines the composition and its preparation/use, ensuring low technical implementation hurdles and easy integration into current biomaterial preparation processes. As it involves standard reagent preparation and immersion steps, rapid technology transfer and operational startup are expected.
Success Scenario
Upon adopting this technology, a licensee's lab could complete complex tissue clearing processes, previously taking several days, within a few hours to half a day. This would enable researchers to analyze more samples rapidly, potentially shortening new drug candidate screening cycles by over 20% annually. Consequently, this could accelerate the entire development pipeline, significantly enhancing market competitiveness.
Patent Record
APPLICATION NO.
特願2023-076864
REGISTRATION NO.
7669054
FILING DATE
2023/05/08
GRANT DATE
2025/04/18
EXPIRATION DATE
2043/05/08
PATENT HOLDER
国立研究開発法人理化学研究所
Examination History
2023年05月08日
出願審査請求書
2024年07月16日
拒絶理由通知書
2024年08月29日
意見書
2024年08月29日
手続補正書(自発・内容)
2024年10月29日
拒絶理由通知書
2024年12月27日
意見書
2024年12月27日
手続補正書(自発・内容)
2025年03月11日
特許査定